Fr. 188.00

Therapeutic Uses of Botulinum Toxin

Anglais · Livre Relié

Expédition généralement dans un délai de 2 à 3 semaines (titre imprimé sur commande)

Description

En savoir plus

Justinius Kerner, a German medical officer and poet, was the first to realize that botulinum toxin potentially might be useful for therapeutic purposes. Kerner made this observation in 1822, but he did not call the toxin "botulinum toxin. " Instead, Kerner called it the substance in "wirkenden stoffes," which translates to "bad sausages. " Kerner realized that there was a "fat poison" or "fatty acid" within sausages that produced the toxic effects that we now know as botulism. Nearly a century would pass before the bacterium producing the toxin would be isolated and the toxin ultimately renamed "botulinum toxin. " As farsighted as Kerner was, it is doubtful that even he could have predicted just how much potential therapeutic punch was packed within his wirkenden stoffes. It was not until 1978, more than a century and a half after Kerner's prediction, that Dr. Allan Scott received Food and Drug Administration approval to test botulinum toxin type A in human volunteers. We do not yet have a comprehensive understanding of precisely how botulinum toxin works in the human body or how our bodies fully respond to the toxin. We do know that it temporarily paralyzes muscle by inhibiting the release of acetylcholine, and it also appears to inhibit the release of other neurotransmitters.

Table des matières

History and Mechanism of Action.- Spasticity.- Radiation Fibrosis Syndrome.- Low Back Pain.- Piriformis Syndrome.- Plantar Fasciitis.- Headache.- Spasmodic Dysphonia.- Sialorrhea and Frey's Syndrome.- Cosmetic Applications.- Hyperhydrosis.- Urological Applications.- Gastrointestinal Applications.- Blepharospasm.- Economics, Immunity, and Future Directions.

Résumé

Justinius Kerner, a German medical officer and poet, was the first to realize that botulinum toxin potentially might be useful for therapeutic purposes. Kerner made this observation in 1822, but he did not call the toxin “botulinum toxin. ” Instead, Kerner called it the substance in “wirkenden stoffes,” which translates to “bad sausages. ” Kerner realized that there was a “fat poison” or “fatty acid” within sausages that produced the toxic effects that we now know as botulism. Nearly a century would pass before the bacterium producing the toxin would be isolated and the toxin ultimately renamed “botulinum toxin. ” As farsighted as Kerner was, it is doubtful that even he could have predicted just how much potential therapeutic punch was packed within his wirkenden stoffes. It was not until 1978, more than a century and a half after Kerner’s prediction, that Dr. Allan Scott received Food and Drug Administration approval to test botulinum toxin type A in human volunteers. We do not yet have a comprehensive understanding of precisely how botulinum toxin works in the human body or how our bodies fully respond to the toxin. We do know that it temporarily paralyzes muscle by inhibiting the release of acetylcholine, and it also appears to inhibit the release of other neurotransmitters.

Texte suppl.

From the reviews:

"This book presents many of the clinical uses of the relatively new drug, botulinum toxin. … the book attempts to cover nearly all uses of the medication known to the assorted authors, including potential treatments for which there is little peer-reviewed literature. The purpose is to provide an overview of this medication, and present clinical scenarios in which the drug might be an appropriate choice. … The target audience should be clinicians (physicians and therapists) ... ." (Ross Bogey, Doody’s Review Service, January, 2008)

Commentaire

From the reviews:

"This book presents many of the clinical uses of the relatively new drug, botulinum toxin. ... the book attempts to cover nearly all uses of the medication known to the assorted authors, including potential treatments for which there is little peer-reviewed literature. The purpose is to provide an overview of this medication, and present clinical scenarios in which the drug might be an appropriate choice. ... The target audience should be clinicians (physicians and therapists) ... ." (Ross Bogey, Doody's Review Service, January, 2008)

Détails du produit

Collaboration Gran Cooper (Editeur), Grant Cooper (Editeur)
Edition Springer, Berlin
 
Langues Anglais
Format d'édition Livre Relié
Sortie 17.04.2009
 
EAN 9781588299147
ISBN 978-1-58829-914-7
Pages 238
Poids 618 g
Illustrations XIV, 238 p.
Thèmes Musculoskeletal Medicine
Musculoskeletal Medicine
Catégorie Sciences naturelles, médecine, informatique, technique > Médecine > Spécialités cliniques

Commentaires des clients

Aucune analyse n'a été rédigée sur cet article pour le moment. Sois le premier à donner ton avis et aide les autres utilisateurs à prendre leur décision d'achat.

Écris un commentaire

Super ou nul ? Donne ton propre avis.

Pour les messages à CeDe.ch, veuillez utiliser le formulaire de contact.

Il faut impérativement remplir les champs de saisie marqués d'une *.

En soumettant ce formulaire, tu acceptes notre déclaration de protection des données.